Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8.

@article{Curfman2005ExpressionOC,
  title={Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8.},
  author={G. Curfman and Stephen Morrissey and J. Drazen},
  journal={The New England journal of medicine},
  year={2005},
  volume={353 26},
  pages={
          2813-4
        }
}
  • G. Curfman, Stephen Morrissey, J. Drazen
  • Published 2005
  • Medicine
  • The New England journal of medicine
  • Drs. Gregory Curfman, Stephen Morrissey, and Jeffrey Drazen report on recently obtained information regarding inaccuracies in data in the report of the Vioxx Gastrointestinal Outcomes Research study that raises concern about certain conclusions in the article. 
    165 Citations
    Expression of concern reaffirmed.
    • 97
    4 years after withdrawal of rofecoxib: where do we stand today?
    • 25
    Conflicts of interest and disclosures in publications.
    • 3
    Peptic ulcer disease
    • J. Louw
    • Medicine
    • Current opinion in gastroenterology
    • 2006
    Unbalanced reporting of benefits and harms in abstracts on rofecoxib
    • 3
    • PDF
    Cerebrovascular Events After Discontinuation of Rofecoxib Treatment
    Drugs and trials: lessons from Plato.
    Practice Advisory on the Appropriate Use of NSAIDs in Primary Care
    The Vioxx® legacy: Enduring lessons from the not so distant past.
    • 3
    • PDF